Heidelberg Pharma AG Announces Results From Research Collaboration With Heidelberg University and the DKFZ to be Presented at ASH Annual Meeting

Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting

- ATAC efficacy evaluated in multiple myeloma cells

- Promising top-line results with HDP-101 available

- Research results to be presented at American Society of Hematology (ASH) Annual Meeting in early December

Ladenburg, Germany, 13 November 2017 - Heidelberg Pharma (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that it will present top-line results from a research collaboration with Heidelberg University and the German Cancer Research Center (DKFZ) led by Dr. Marc-Steffen Raab at the 59th ASH (American Society of Hematology) Annual Meeting, the leading conference for hematologic diseases, taking place from 9 to 12 December 2017 in Atlanta, GA, USA.

The collaboration evaluated the efficacy of the development candidate HDP-101 on multiple myeloma cells isolated from patients. HDP-101 consists of a BCMA antibody, a specific linker and the toxin Amanitin. BCMA (B-cell maturation antigen) is a surface protein that is selectively expressed in multiple myeloma cells and to which the selected antibody specifically binds. In the jointly conducted preclinical study, non-dividing cancer cells taken from multiple myeloma patients were examined with HDP-101. A strong cytotoxic effect was observed including at very low doses, even in cancer cells with a low concentration of BCMA antigens. No toxicity was observed on non-BCMA expressing control cells. This is the first time that the efficacy of Amanitin on cancer cells taken from human patients was demonstrated.

Antibody drug conjugates (ADCs) with Amanitin represent a novel therapeutic approach for treating multiple myeloma. The toxin’s biological mode of action could break through drug resistance and improve the prognosis of patients. Heidelberg Pharma expects to initiate a clinical trial with HDP-101 by the end of 2018.

Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma AG, commented: “This preclinical study in multiple myeloma carried out jointly with Heidelberg University and the DKFZ demonstrates the effect of our candidate HDP-101 on tumor cells isolated directly from patients, providing us with further important support of the efficacy of our first proprietary ATAC candidate HDP-101, which is of major importance to us. We are delighted that the results will be presented at such an important event as the ASH Annual Meeting.”

Presentation details:

Poster: 3070 Preclinical Evaluation of HDP-101, a Novel Anti-Bcma Antibody-Drug Conjugate, in Multiple Myeloma
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Date: Sunday, 10 December 2017
Time: 6:00 - 8:00 pm
Place: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

The abstract is available online and will also be published in a special issue of “Blood” on 8 December 2017.

About Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON^(R) and REDECTANE^(R), while RENCAREX^(R) is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.